Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Ocrelizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Genentech`s Biologic Ocrevus (Ocrelizumab) Receives Approval in US
    Genentech`s Biologic Ocrevus (Ocrelizumab) Receives Approval in US

    13 Sep 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761371

    FDA
    13 Sep 2024
    Share Share
    FDA Approves Roche's Subcutaneous OCREVUS ZUNOVO With ENHANZE
    FDA Approves Roche's Subcutaneous OCREVUS ZUNOVO With ENHANZE

    13 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/halozyme-announces-fda-approval-of-roches-subcutaneous-ocrevus-zunovo-with-enhanze-for-people-with-relapsing-and-primary-progressive-multiple-sclerosis-302247928.html

    PR NEWSWIRE
    13 Sep 2024
    Share Share
    NHS rolls out “more convenient” Ocrevus injection for multiple sclerosis
    NHS rolls out “more convenient” Ocrevus injection for multiple sclerosis

    12 Jul 2024

    // Robert Barrie PHARMACEUTICAL-TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/nhs-rolls-out-more-convenient-ocrevus-injection-for-multiple-sclerosis/

    Robert Barrie PHARMACEUTICAL-TECHNOLOGY
    12 Jul 2024
    Share Share
    Genentech Inc Biologic Ocrelizumab Receives Approval in US
    Genentech Inc Biologic Ocrelizumab Receives Approval in US

    21 Jun 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761053

    FDA
    21 Jun 2024
    Share Share
    Roche touts near-complete MS suppression for injectable Ocrevus
    Roche touts near-complete MS suppression for injectable Ocrevus

    17 Apr 2024

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/pharma/roche-touts-near-complete-suppression-multiple-sclerosis-relapse-injectable-ocrevus

    Angus Liu FIERCE PHARMA
    17 Apr 2024
    Share Share
    Genentech`s Biologic Ocrevus (ocrelizumab) Receives Approval in the U.S.
    Genentech`s Biologic Ocrevus (ocrelizumab) Receives Approval in the U.S.

    19 Jan 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761053

    FDA
    19 Jan 2024
    Share Share